{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:03:19Z","timestamp":1790370199446,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,3,1]],"date-time":"2027-03-01T00:00:00Z","timestamp":1803859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,3,1]],"date-time":"2027-03-01T00:00:00Z","timestamp":1803859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 112-2628-H-037 -002 -MY3"],"award-info":[{"award-number":["NSTC 112-2628-H-037 -002 -MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2027,3]]},"DOI":"10.1016\/j.vhri.2026.101654","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:35:53Z","timestamp":1780461353000},"page":"101654","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cost-Effectiveness of Universal Newborn Screening and Disease-Modifying Therapies for Spinal Muscular Atrophy in Taiwan"],"prefix":"10.1016","volume":"58","author":[{"given":"Wan-Ling","family":"Chiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuh-Jyh","family":"Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Prosser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huey-Fen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Min","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vhri.2026.101654_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/TACG.S239603","article-title":"Spinal muscular atrophy: mutations, testing, and clinical relevance","volume":"14","author":"Keinath","year":"2021","journal-title":"Appl Clin Genet"},{"key":"10.1016\/j.vhri.2026.101654_bib2","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jpeds.2017.06.042","article-title":"Presymptomatic diagnosis of spinal muscular atrophy through newborn screening","volume":"190","author":"Chien","year":"2017","journal-title":"J Pediatr"},{"issue":"2","key":"10.1016\/j.vhri.2026.101654_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017067","article-title":"Carrier screening for spinal muscular atrophy (SMA) in 107,611 pregnant women during the period 2005-2009: a prospective population-based cohort study","volume":"6","author":"Su","year":"2011","journal-title":"PLOS One"},{"issue":"5","key":"10.1016\/j.vhri.2026.101654_bib4","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/ana.20473","article-title":"Natural history of denervation in SMA: relation to age, SMN2 copy number, and function","volume":"57","author":"Swoboda","year":"2005","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.vhri.2026.101654_bib5","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s00439-006-0156-7","article-title":"Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number","volume":"119","author":"Wirth","year":"2006","journal-title":"Hum Genet"},{"issue":"7","key":"10.1016\/j.vhri.2026.101654_bib6","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.nmd.2015.04.009","article-title":"209th ENMC International Workshop: Outcome Measures and Clinical Trial Readiness in Spinal Muscular Atrophy 7-9 November 2014, Heemskerk, The Netherlands","volume":"25","author":"Finkel","year":"2015","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"10.1016\/j.vhri.2026.101654_bib7","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41572-022-00380-8","article-title":"Spinal muscular atrophy","volume":"8","author":"Mercuri","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.vhri.2026.101654_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.spen.2021.100878","article-title":"Spinal muscular atrophy","volume":"37","author":"Nicolau","year":"2021","journal-title":"Semin Pediatr Neurol"},{"issue":"11","key":"10.1016\/j.vhri.2026.101654_bib10","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study","volume":"29","author":"De Vivo","year":"2019","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"10.1016\/j.vhri.2026.101654_bib11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.27853","article-title":"Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study","volume":"68","author":"Crawford","year":"2023","journal-title":"Muscle Nerve"},{"issue":"7","key":"10.1016\/j.vhri.2026.101654_bib12","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","article-title":"Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.vhri.2026.101654_bib13","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","article-title":"Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat Med"},{"issue":"18_supplement","key":"10.1016\/j.vhri.2026.101654_bib14","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1212\/WNL.98.18_supplement.1636","article-title":"Rainbowfish: preliminary efficacy and safety data in risdiplam-treated infants with presymptomatic SMA (P17-5.003)","volume":"98","author":"Finkel","year":"2022","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.vhri.2026.101654_bib15","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.pediatrneurol.2015.06.002","article-title":"Delay in diagnosis of spinal muscular atrophy: a systematic literature review","volume":"53","author":"Lin","year":"2015","journal-title":"Pediatr Neurol"},{"issue":"1","key":"10.1016\/j.vhri.2026.101654_bib16","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.braindev.2020.07.012","article-title":"Natural history in spinal muscular atrophy Type I in Taiwanese population: a longitudinal study","volume":"43","author":"Ou","year":"2021","journal-title":"Brain Dev"},{"issue":"6","key":"10.1016\/j.vhri.2026.101654_bib17","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.nmd.2021.03.007","article-title":"Newborn screening programs for spinal muscular atrophy worldwide: where we stand and where to go","volume":"31","author":"Dangouloff","year":"2021","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"10.1016\/j.vhri.2026.101654_bib18","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200224","article-title":"Life-saving treatments for spinal muscular atrophy: global access and availability","volume":"14","author":"Armengol","year":"2024","journal-title":"Neurol Clin Pract"},{"issue":"2","key":"10.1016\/j.vhri.2026.101654_bib19","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/ijns9020020","article-title":"Implementation of newborn screening for conditions in the United States first recommended during 2010-2018","volume":"9","author":"Singh","year":"2023","journal-title":"Int J Neonatal Screen"},{"key":"10.1016\/j.vhri.2026.101654_bib20","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jpeds.2020.07.033","article-title":"Cost-effectiveness of nusinersen and universal newborn screening for spinal muscular atrophy","volume":"227","author":"Jalali","year":"2020","journal-title":"J Pediatr"},{"issue":"12","key":"10.1016\/j.vhri.2026.101654_bib21","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/jnnp-2021-326344","article-title":"Newborn screening for spinal muscular atrophy with disease-modifying therapies: a cost-effectiveness analysis","volume":"92","author":"Shih","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"10.1016\/j.vhri.2026.101654_bib22","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.jval.2022.06.010","article-title":"Cost-effectiveness of newborn screening for spinal muscular atrophy in the Netherlands","volume":"25","author":"Velikanova","year":"2022","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.vhri.2026.101654_bib23","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s40120-023-00489-2","article-title":"Cost-effectiveness of newborn screening for spinal muscular atrophy in England","volume":"12","author":"Weidlich","year":"2023","journal-title":"Neurol Ther"},{"key":"10.1016\/j.vhri.2026.101654_bib24","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.nmd.2023.11.013","article-title":"Cost-effectiveness of spinal muscular atrophy newborn screening based on real-world data in Belgium","volume":"34","author":"Dangouloff","year":"2024","journal-title":"Neuromuscul Disord"},{"issue":"9","key":"10.1016\/j.vhri.2026.101654_bib25","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s40261-024-01386-8","article-title":"Cost-effectiveness analysis of newborn screening for spinal muscular atrophy in Italy","volume":"44","author":"Ghetti","year":"2024","journal-title":"Clin Drug Investig"},{"issue":"1","key":"10.1016\/j.vhri.2026.101654_bib26","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1080\/13696998.2024.2439734","article-title":"Cost-utility analysis of newborn screening for spinal muscular atrophy in Japan","volume":"28","author":"Hata","year":"2025","journal-title":"J Med Econ"},{"issue":"1","key":"10.1016\/j.vhri.2026.101654_bib27","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1186\/s13023-025-03927-6","article-title":"A cost-utility analysis of newborn screening for spinal muscular atrophy in Canada","volume":"20","author":"Pace","year":"2025","journal-title":"Orphanet J Rare Dis"},{"issue":"Suppl 1","key":"10.1016\/j.vhri.2026.101654_bib28","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.pedneo.2022.11.001","article-title":"The modern face of newborn screening","volume":"64","author":"Chien","year":"2023","journal-title":"Pediatr Neonatol"},{"issue":"1","key":"10.1016\/j.vhri.2026.101654_bib29","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s13023-025-03697-1","article-title":"Newborn screening facilitates early theranostics and improved spinal muscular atrophy outcome: five-year real-world evidence from Taiwan","volume":"20","author":"Wang","year":"2025","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"10.1016\/j.vhri.2026.101654_bib30","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41436-020-00987-w","article-title":"CMAP changes upon symptom onset and during treatment in spinal muscular atrophy patients: lessons learned from newborn screening","volume":"23","author":"Weng","year":"2021","journal-title":"Genet Med"},{"key":"10.1016\/j.vhri.2026.101654_bib31","series-title":"Cost effectiveness and strategic planning (WHO-CHOICE)","year":"2021"},{"issue":"9","key":"10.1016\/j.vhri.2026.101654_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044043","article-title":"Cost per QALY (quality-adjusted life year) and lifetime cost of prolonged mechanical ventilation in Taiwan","volume":"7","author":"Hung","year":"2012","journal-title":"PLOS One"},{"issue":"23","key":"10.1016\/j.vhri.2026.101654_bib34","doi-asserted-by":"crossref","first-page":"8989","DOI":"10.3390\/ijerph17238989","article-title":"The burden of spinal muscular atrophy on informal caregivers","volume":"17","author":"Aranda-Reneo","year":"2020","journal-title":"Int J Environ Res Public Health"},{"issue":"2","key":"10.1016\/j.vhri.2026.101654_bib35","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1378\/chest.125.2.597","article-title":"Prevalence and outcomes of caregiving after prolonged (> or =48 hours) mechanical ventilation in the ICU","volume":"125","author":"Im","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.vhri.2026.101654_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.1054931","article-title":"Utility estimations of different health states of patients with type I, II, and III spinal muscular atrophy in China: a mixed approach study with patient and proxy-reported data","volume":"10","author":"Hu","year":"2022","journal-title":"Front Public Health"},{"issue":"6","key":"10.1016\/j.vhri.2026.101654_bib37","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00439-002-0828-x","article-title":"Genetic testing and risk assessment for spinal muscular atrophy (SMA)","volume":"111","author":"Ogino","year":"2002","journal-title":"Hum Genet"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109926000695?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109926000695?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:38:48Z","timestamp":1790368728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109926000695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,3]]},"references-count":35,"alternative-id":["S2212109926000695"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2026.101654","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2027,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Universal Newborn Screening and Disease-Modifying Therapies for Spinal Muscular Atrophy in Taiwan","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2026.101654","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society for Pharmacoeconomics and Outcomes Research, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101654"}}